View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 9, 2022

University of Surrey scientists unveil new approach to treat brain tumours

The research project was conducted in partnership with the universities of Surrey, Leeds and Texas, as well as HOX Therapeutics.

Researchers from the University of Surrey have showed in a study that a short chain of amino acids, HTL-001 peptide, is effective for target and inhibition of the function of Hox genes that causes growth of glioblastoma multiforme (GBM). 

These findings are obtained from a seven-year research project carried out in cell and animal models.  

The project was conducted in partnership with the universities of Surrey, Leeds and Texas and HOX Therapeutics.

HOX Therapeutics, the University of Surrey’s start-up firm, is in the Surrey Research Park.

The HTL-001 peptide analysed in the study has been tested for safety and is claimed to be fit for subject trials. 

Currently, these trials are being explored to treat GBM and other cancers. 

A family of genes, Hox genes are crucial for proper brain tissue growth but are usually silenced at birth following robust activity in the developing embryo. 

However, if they are ‘switched on’ again incorrectly, their activity can cause cancer progression. 

Dysregulation of Hox gene has been associated with GBM.  

University of Surrey Medical Oncology professor and project lead Hardev Pandha said: “People who suffer from Glioblastoma Multiforme have a five per cent survival rate over a five-year period – a figure that has not improved in decades. 

“While we are still early in the process, our seven-year project offers a glimmer of hope for finding a solution to Hox gene dysregulation, which is associated with the growth of GBM and other cancers, and which has proven to be elusive as a target for so many years.” 

GBM is a common and devastating kind of brain cancer in adults.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU